ArticleBMC biotechnology2026
Propolis-functionalized acellular fish skin scaffolds as biotechnological platforms for antimicrobial activity and regenerative wound healing.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiotechnological advances in tissue engineering increasingly exploit naturally derived scaffolds as bioactive delivery systems. Acellular fish skin (AFS) provides a collagen-rich extracellular matrix favorable for tissue regeneration but lacks intrinsic antimicrobial activity. Propolis, a polyphenol-rich natural resin, exhibits antimicrobial, antioxidant, and immunomodulatory properties, yet its direct application is limited by burst release and local cytotoxicity. In this study, we aimed to develop and characterize a propolis-functionalized AFS scaffold as a multifunctional biomaterial capable of combining sustained antimicrobial activity with regenerative support for wound-healing applications.
resultsLipid-preserved Tilapia-derived AFS was biofunctionalized with ethanolic propolis extract (EPE) through a vacuum-assisted impregnation process to obtain an EPE-AFS hybrid scaffold. The biotechnological modification preserved the collagenous architecture and porosity of the matrix, enhanced surface hydrophilicity (contact angle reduced from 91° ± 2° to 67° ± 3°), and maintained mechanical integrity (~ 13 MPa). Spectroscopic and microscopic analyses (FTIR, FE-SEM) confirmed successful deposition of polyphenolic components. The release profile demonstrated sustained polyphenol diffusion over 96 h (> 90% cumulative release). Functionally, cellular assays confirmed enhanced fibroblast adhesion and migration on propolis-functionalized scaffolds. Gene expression analysis revealed transcriptional upregulation of extracellular matrix remodeling and angiogenesis-associated markers (COL1A1, COL3A1, VEGF, TGF-β1), alongside downregulation of inflammation-related transcripts (IL-6, MMP-9). Antibacterial evaluation based on turbidity measurements indicated effective growth inhibition against Staphylococcus aureus and Escherichia coli.
conclusionsThis study demonstrates a biotechnological strategy for functionalizing natural collagen scaffolds with propolis-derived polyphenols, yielding a dual-action biomaterial that combines sustained antibacterial growth suppression with enhanced regenerative-associated signaling in vitro. The EPE–AFS construct represents a promising nature-derived platform for further preclinical investigation in wound-healing applications. While these findings reveal a pro-regenerative and anti-inflammatory transcriptional profile in fibroblasts, additional validation—including endothelial and immune cell functional assays and in vivo wound models—is required to confirm angiogenic, immunomodulatory, and therapeutic efficacy under physiologically relevant conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.